http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오다현,배재호,안상욱,한윤수 한국공업화학회 2020 한국공업화학회 연구논문 초록집 Vol.2020 No.-
Carbazole-based materials such as 4,4'-bis(N-carbazolyl)-2,2'-biphenyl (CBP) and its derivatives are frequently used as host materials in organic light emitting diodes with high hole mobility. This is due to its electron-rich property from two carbazolyl units. In this study, all solid-state DSSCs with 4,4'-bis(3-ethyl- N-carbazolyl)-1,1'-biphenyl (ethyl CBP) as a hole transporting material were fabricated, and their photovoltaic properties were investigated. When the ethyl CBP doped with 1-methyl-3-propylimidazolium iodide (MPII) and bis(trifluoromethane) sulfonimide lithium salt was used, a solid state DSSC showed a power conversion efficiency(PCE) of 0.453%, resulting from 0.998 mA/㎠ of the short-circuit current, 0.672 V of the open-circuit voltage and 67.50% of the fill factor.
오다현,김진아,한윤수 한국공업화학회 2020 한국공업화학회 연구논문 초록집 Vol.2020 No.-
Nowadays, a great deal of research work has been focusing on searching for efficient solid-state hole transporting materials to replace redox mediators in liquid electrolytes. In this study, all solid-state DSSCs with 3,3'',6,6''-tetrakis(1,1-dimethylethyl)-9'-ethyl-9,3':6',9''-ter-9H-carbazole (TBu-TCz) as a hole transporting material were fabricated, and their photovoltaic properties were investigated. When the TBu-TCz doped with 1-methyl-3-propylimidazolium iodide (MPII) was used, a solid state DSSC showed a power conversion efficiency(PCE) of 0.974%, resulting from 2.224 mA/㎠ of the short-circuit current (Jsc), 0.626 V of the open-circuit voltage (Voc) and 69.98% of fill factor (FF). On the other hand, a device, in which the TBu-TCz was doped with both MPII and bis(trifluoromethane)sulfonimide lithium salt, showed a photovoltaic performance of 3.764 mA/㎠ for the Jsc, 0.606 V for the Voc, and 69.95% for the FF, which led to a PCE of 1.595%.
국내 병원획득 폐렴 원인균의 경험적 항균제에 대한 내성 현황
오다현,김윤숙,천부순 한국병원약사회 2018 병원약사회지 Vol.35 No.1
Background : Although the prevalence of antibiotic resistance may vary according to region, there is no guidance developed in Korea on the use of empirical antibiotics for the treatment of hospitalacquired pneumonia (HAP). The purpose of this study was to investigate the patterns of empiric antibiotic therapy and resistance of the isolated pathogens to the empirical antibiotics in the management of HAP in Korea. Methods : A retrospective analysis was conducted using the electronic medical records of the HAP patients January 2014-December 2015 in Korea. The patterns of prescribing empirical antibiotics and resistance of the isolated pathogens to the empirical antibiotics were examined. Results : A total of 170 patients was analyzed. Piperacillin/tazobactam was the key agent in the empirical antibiotics. The most common pathogen was Staphylococcus aureus (27.9%) followed by Acinetobacter baumannii (21.6%), Klebsiella pneumoniae (11.1%), Pseudomonas aeruginosa (6.3%), Stenotrophomonas maltophilia (5.8%), Enterobacter aerogenes (5.3%), and Escherichia coli (5.3%). The resistance rates of S. aureus to ciprofloxacin was 76%. E. coli had high level of resistance rate to ciprofloxacin (80%) and low resistance rate to imipenem (10%). K. pneumoniae and P. aeruginosa showed very high level of sensitivity to imipenem (100%) and cefepime (91.7%), respectively. To piperacillin/tazobactam, E. coli, E. erogenes, K. pneumoniae, and P. aeruginosa showed high level of sensitivity (52.4-100%). A. baumannii exhibited high-level resistance rates (63.4-85.4%) to the empirical antibiotics, including cefepime, ceftazidime, ciprofloxacin, imipenem, and piperacillin/tazobactam. Conclusion : The empirical antibiotic therapy was appropriate for the initial treatment of HAP owing to the adequate antibiotic coverage. Piperacillin/tazobactam was used in most patients and the most common pathogens including Pseudomonas aeruginosa had high level of sensitivity to the drug. The high level of resistance of A. baumannii to the empirical antibiotics is one of the major challenges in treating HAP.
ABCG2 C421A 다형성이 만성 골수성 백혈병 환자의 imatinib 치료에 미치는 영향 : 체계적 문헌고찰 및 메타분석
오다현,천부순 한국임상약학회 2016 한국임상약학회지 Vol.26 No.1
Objective: To estimate the association between ABCG2 C421A polymorphism and response to imatinib in chronic myeloid leukemia. Methods: A systematic review was conducted to evaluate the effect of ABCG2 C421A polymorphism on imatinib response. The databases of PubMed, Embase, Web of science, CINAHL with FullText, and Cochrane Library were searched for all published studies from inception to December 2015. The following terms were used with functions of ‘AND’ and ‘OR’: ‘chronic myeloid leukemia’, ‘CML’, ‘drug transporter’, ‘ABCG2’, ‘BCRP’, ‘polymorphisms’, ‘SNPs’, and ‘imatinib’. The studies reporting the association between ABCG2 polymorphism and imatinib response were evaluated. Results: A total of 7 studies were included in the present meta-analysis. The pooled analysis showed that ABCG2 c.421CC genotype was significantly associated with poor response to imatinib under the dominant model (CC vs CA+AA; OR: 0.56; 95% CI: 0.41, 0.77; p = 0.0004). The subgroup analysis of Asian studies demonstrated a significantly lower response in c.421CC genotype than in c.421CA or c.421AA genotype (OR: 0.52; 95% CI: 0.37, 0.73; p = 0.0002). In subgroup analyses of 5 studies, the patients with the c.421CC genotype exhibited higher risk for worse response than the patients with c.421CA or c.421AA genotype (heterozygote codominant model: CC vs. AC; OR: 0.49, 95% CI: 0.33, 0.73; p = 0.0006; homozygote codominant model: CC vs AA; OR: 0.43; 95% CI: 0.25, 0.75, p = 0.003). Conclusion: The ABCG2 c.421CC genotype was significantly associated with poor response to imatinib compared to the c.421CA and c.421AA genotypes in chronic myeloid leukemia, especially in Asian patients.
오다현,천부순 한국임상약학회 2016 한국임상약학회지 Vol.26 No.1
Objective: To estimate the association between ABCG2 C421A polymorphism and response to imatinib in chronic myeloid leukemia. Methods: A systematic review was conducted to evaluate the effect of ABCG2 C421A polymorphism on imatinib response. The databases of PubMed, Embase, Web of science, CINAHL with FullText, and Cochrane Library were searched for all published studies from inception to December 2015. The following terms were used with functions of ‘AND’ and ‘OR’: ‘chronic myeloid leukemia’, ‘CML’, ‘drug transporter’, ‘ABCG2’, ‘BCRP’, ‘polymorphisms’, ‘SNPs’, and ‘imatinib’. The studies reporting the association between ABCG2 polymorphism and imatinib response were evaluated. Results: A total of 7 studies were included in the present meta-analysis. The pooled analysis showed that ABCG2 c.421CC genotype was significantly associated with poor response to imatinib under the dominant model (CC vs CA+AA; OR: 0.56; 95% CI: 0.41, 0.77; p = 0.0004). The subgroup analysis of Asian studies demonstrated a significantly lower response in c.421CC genotype than in c.421CA or c.421AA genotype (OR: 0.52; 95% CI: 0.37, 0.73; p = 0.0002). In subgroup analyses of 5 studies, the patients with the c.421CC genotype exhibited higher risk for worse response than the patients with c.421CA or c.421AA genotype (heterozygote codominant model: CC vs. AC; OR: 0.49, 95% CI: 0.33, 0.73; p = 0.0006; homozygote codominant model: CC vs AA; OR: 0.43; 95% CI: 0.25, 0.75, p = 0.003). Conclusion: The ABCG2 c.421CC genotype was significantly associated with poor response to imatinib compared to the c.421CA and c.421AA genotypes in chronic myeloid leukemia, especially in Asian patients.